How we describe inequality is significant because it impacts our view of who causes it and how society should address it. Photo via Getty Images

Look closely at any news article about inequality and you will quickly notice that there is more than one way to describe what is happening.

For example:

“In 2022, men earned $1.18 for every dollar women earned.”

“In 2022, women earned 82 cents for every dollar men earned.”

“In 2022, the gender wage gap was 18 cents per dollar.”

When pointing out differences in access to resources and opportunities among groups of people, we tend to use three types of language:

  1. Advantaged — Describes an issue in terms of advantages the more dominant group enjoys.
  2. Disadvantaged — Describes an issue in terms of disadvantages the less dominant group experiences.
  3. Neutrality — Stays general enough to avoid direct comparisons between groups of people.

The difference between these three lenses, referred to as “frames” in academic literature, may be subtle. We may miss it completely when skimming a news article or listening to a friend share an opinion. But frames are more significant than we may realize.

“Frames of inequality matter because they shape our view of what is wrong and what should be fixed,” says Rice Business Professor Sora Jun.

Jun led a research team that conducted multiple studies to understand which of the three frames people typically use to describe social and economic inequality. In total, they analyzed more than 19,000 mainstream media articles and surveyed more than 600 U.S.-based participants.

In Chronic frames of social inequality: How mainstream media frame race, gender, and wealth inequality, the team published two major findings.

First, people tend to describe gender and racial inequality using the language of disadvantage. For example, “The data showed that officers pulled over Black drivers at a rate far out of proportion to their share of the driving-age population.”

Jun’s team encountered the same rhetorical tendency with gender inequality. In most cases, people describe instances of gender inequality (e.g., the gender pay gap) in terms of a disadvantage for women. We are far more likely to use the statement “Women earned 82 cents for every dollar men earned” than “Men earned $1.18 cents for every dollar women earned.”

"We expected that people would use the disadvantage framework to describe racial and gender inequalities, and it turned out to be true,” says Jun. “We think that the reason for this stems from how legitimate we perceive different hierarchies to be.” Because demographic categories like gender and race are unrelated to talent or effort, most people find it unfair that resources are distributed unevenly along these lines.

On the other hand, Jun expected people to describe wealth inequality in terms of advantage rather than disadvantage. The public typically considers this form of inequality to be more fair than racial or gender inequality. “In the U.S., there is still a widespread belief in economic mobility — that if you work hard enough, you can change the socioeconomic group you are in,” she says.

But in their second major finding, she and fellow researchers discovered that the most common frame used to describe wealth inequality was no frame at all. We find this neutrality in statements like “Disparities in education, health care and social services remain stark.”

Jun is not sure why people take a neutral approach more frequently when describing wealth inequality (speaking specifically of economic classes outside of gender and race). She suspects it has something to do with the fact that we view wealth as a fluid and continuous spectrum.

The merits of the three frames are up for debate. Using the frame of disadvantage might seem to portray issues more sympathetically, but some scholars point to potential downsides. The language of disadvantage installs the dominant group as the measuring stick for everyone else. It may also put the onus of change on the disadvantaged group while making the problem seem less relevant to the dominant group.

“When we speak about the gender gap in terms of disadvantage, and helping women earn more compared to men, we automatically assume that men are making the correct amount,” says Jun. “But maybe we should be looking at both sides of the equation.”

On the other hand, Jun cautions against using a one-size-fits-all approach to describing inequality. “We have to be careful not to jump to an easy conclusion, because the causes of inequality are so vast,” she says.

For example, men tend to interrupt conversations in team meetings at higher rates than women. “Should we frame this behavior in terms of advantage or disadvantage, which naturally leads us to prompt men to interrupt less and women to interrupt more?” asks Jun. “We really don’t know until we understand the ideal number of interruptions and why this deviation is happening. Ultimately, how we talk about inequality depends on what we want to accomplish. I hope that through this research, people will think more carefully about how they describe inequality so that they capture the full story before they act.”

------

This article originally ran on Rice Business Wisdom and was based on research from Sora Jun, Rosalind M. Chow, A. Maurits van der Veen and Erik Bleich.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

New Houston biotech co. lands $30M for pulmonary fibrosis drug

drug money

Most of us can claim a scar or two on our bodies. But when scarring develops inside the body, it’s known as a fibrotic disorder. A freshly launched Houston company, Oorja Bio Inc., is working on a treatment that can help to repair cells and reduce the damage wrought by the growth of fibrotic tissue in patients.

Late last month, Oorja Bio hit the scene with a pair of big announcements. Not only has the company raised a $30 million Series A thanks to founding investor California-based Westlake BioPartners, but it has also already paved the way for a Phase 2 study to take place this year.

Oorja Bio received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA), allowing the company to test its treatment in patients with idiopathic pulmonary fibrosis (IPF), a scarring of the lung tissue. IPF affects more than 150,000 adults in the United States and can result in a range of symptoms from shortness of breath to organ failure and death as it progresses.

Oorja Bio’s lead drug candidate, ORJ-001, was shown in a Phase 1 in-human trial to demonstrate “therapeutically relevant exposure and favorable tolerability” in 64 healthy adult volunteers in whom it was administered daily or weekly, according to a news release. Pre-clinical studies of ORJ-001 showed durable target tissue engagement and biomarker activity in bleomycin-induced lung fibrosis.

Administered subcutaneously, ORJ-001 is intended to improve and even restore function in cells that can reduce the signaling that causes IPF. It stops advancement of IPF and also allows for tissue repair. Currently available treatments for the disease can slow the development of IPF down, but do not address the declining lung function that’s inherent in its progression.

“The clinical and preclinical results from our studies to date give us confidence that ORJ-001 represents a novel treatment approach with the potential to repair and reverse fibrosis and modify disease progression in IPF,” Dr. Janethe Pena, CMO of Oorja Bio, said in the release.

“Our team is energized to deliver on our goal of redefining the future of fibrotic diseases, beginning with ORJ-001,” CEO and founder Sujay Kango added. “As we advance ORJ-001 in the clinic, we are embracing the paradigm shift in our biological understanding of IPF pathology that aligns with the central role of the alveolar epithelium. ORJ-001 was designed with this biology in mind and may provide, for the first time, a therapeutic intervention that repairs and reverses fibrosis and promotes disease modification.”

Most patients live only three to five years following their IPF diagnosis. Soon, ORJ-001 and Oorja Bio could give them a fighting chance.

Axiom Space tops $525M in oversubscribed round, announces Swiss subsidiary

funding boost

Axiom Space tacked on an additional $175 million to a previously announced capital raise, bringing the oversubscribed round to a total of more than $525 million.

Axiom shared in February that it had secured $350 million in a financing round led by Type One Ventures and Qatar Investment Authority. In the latest release from the company, Axiom reports that Japan-based MUFG Bank Ltd. joined the round as a new investor, in addition to continued participation from existing backers.

The funding will go toward developing the company's commercial space station, known as Axiom Station, and the production of its Axiom Extravehicular Mobility Unit (AxEMU) under its NASA spacesuit contract.

“Investor interest in this round outpaced what we set out to raise, which speaks to the moment we’re in,” Jonathan Cirtain, CEO and president of Axiom Space, said in the news release. “Our partners see what is possible in low-Earth orbit, and they see who is positioned to lead it.”

Axiom announced last month that it planned to open a Japanese subsidiary July 1. Earlier this week, it also shared plans to establish Axiom Space Switzerland, a wholly owned subsidiary based in Lucerne that is also expected to begin operations this summer.

The Switzerland subsidiary aims to establish Axiom's presence in Europe and help it partner with the European Space Agency and other space organizations and companies on the continent.

“Europe is a founding leader in the creation of the commercial space economy, and Switzerland is uniquely positioned to convene the government agencies, research institutions, and industrial entities that will shape its next decade,” Cirtain added in a separate release. “Axiom Space Switzerland facilitates the scaling of development and deployment of the infrastructure that will succeed the International Space Station.”

Texas cashes in among 10 best U.S. state economies in 2026 report

State Economics

A new study gauging the success or decline in economic performance in every state has revealed Texas' economy remains stable in 2026 after it dropped out of the top five to No. 8 last year.

Texas boasts the No. 8 best state economy in the U.S. this year, according to WalletHub's annual "Best & Worst State Economies" report. The personal finance website's analysts ranked all 50 states and the District of Columbia across 28 relevant metrics to measure each state's economic activity and health status, and its "innovation potential."

Notably, Texas leads the nation for the most exports per capita in the U.S. in a five-way tie with Louisiana, Kentucky, North Dakota, and Indiana. Across the study's three main categories, Texas ranked highly for its economic activity (No. 7) and economic health (No. 11), and the state's "innovation potential" rank is the 24th best in the nation.

This is how WalletHub ranked Texas' economic performance, where No. 1 is considered the best and No. 25 is considered average:
  • No. 6 – Change in non-farm payrolls
  • No. 8 – Change in GDP
  • No. 8 – Startup activity
  • No. 11 – Annual median household income
  • No. 18 – Government surplus/deficit per capita
  • No. 21 – Percentage of jobs in high-tech industries
  • No. 30 – Unemployment rate
WalletHub previously ranked Texas one of the top three states to start a business in 2026, with Houston earning its own entrepreneurial acclaim in separate rankings of the best big cities for new businesses and for starting a career.

"U.S. economic growth depends heavily on the performance of individual states, and some contribute more than others," the report's author wrote. "For example, California, Texas, New York and Florida have economies so large that if they were countries, they would rank in the top 20 in the world."

The five states with the worst state economies in 2026 are Rhode Island (No. 47), Maine (No. 48), Louisana (No. 49), Kentucky (No. 50), and West Virginia (No. 51).

The top 10 best state economies for 2026 are:

  • No. 1 – Massachusetts
  • No. 2 – Washington
  • No. 3 – Utah
  • No. 4 – California
  • No. 5 – Delaware
  • No. 6 – North Carolina
  • No. 7 – New York
  • No. 8 – Texas
  • No. 9 – Colorado
  • No. 10 – Florida

---

This article originally appeared on CultureMap.com.